Chemotherapeutic and Targeted Drugs in Antitumor Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 15 February 2026 | Viewed by 283
Special Issue Editors
Interests: drug discovery; combination studies; multiple myeloma; real-time imaging; impedance-based cell viability assay
Interests: cell physiology; drug targeting; chemotaxis; apoptosis; impedimetry assays
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Classical chemotherapies non-selectively target rapidly dividing cells, affecting both cancerous and healthy tissues. In contrast, targeted therapies are designed to act on specific cell populations characterized by well-defined molecular markers (e.g., trastuzumab targeting HER2-positive cells). The benefits of targeted therapies have revolutionized oncology by enabling more personalized and effective treatments. Nevertheless, the role of classical chemotherapeutic agents remains essential and continues to form the backbone of many cancer treatment regimens. According to the World Health Organization, cancer is a leading cause of death worldwide (around 10 million deaths per year); therefore, intensive research of either new chemotherapeutics, targeted therapies or their combination is crucial.
We invite researchers to contribute to this Special Issue "Chemotherapeutic and Targeted Drugs in Antitumor Therapy," which aims to provide a comprehensive overview of novel antitumor treatments and the latest findings to outline the possible future perspectives. Submissions focusing on innovative therapeutic strategies—both in vitro and in vivo—are highly encouraged.
Dr. Angéla Takács
Dr. László Kőhidai
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- drug discovery
- small-molecule drugs
- targeted therapy
- combination therapy
- synergism
- selectivity
- immunotherapy
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
